Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%) (%)
Form 8-K Table 3 / 3a / 3b Product Sales
Latest, FY2025
7.0%
Period ended Dec 31, 2025
Change on a year earlier
-11.0 pts
18.0% in FY2024
History
8 years
Since FY2017
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.0% | -11.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 18.0% | -1.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 19.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 20.0% | -10.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 30.0% | -25.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | 55.0% | -33.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 88.0% | -84.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 172.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_keytruda_ww_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.